Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial

DSpace Repository

Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial

Author: Mayer, Katharina; Hein-Rothweiler, Ralph; Schupke, Stefanie; Janisch, Marion; Bernlochner, Isabell; Ndrepepa, Gjin; Sibbing, Dirk; Gori, Tommaso; Borst, Oliver; Holdenrieder, Stefan; Kupka, Danny; Petzold, Tobias; Bradaric, Christian; Okrojek, Rainer; Leistner, David M.; Trippel, Tobias D.; Muenzel, Thomas; Landmesser, Ulf; Pieske, Burkert; Zeiher, Andreas M.; Gawaz, Meinrad P.; Hapfelmeier, Alexander; Laugwitz, Karl-Ludwig; Schunkert, Heribert; Kastrati, Adnan; Massberg, Steffen
Tübinger Autor(en):
Borst, Oliver
Gawaz, Meinrad Paul
Published in: Jama Cardiology (2021), Bd. 6, H. 7, S. 753-761
Verlagsangabe: Chicago
Language: English
Full text: http://dx.doi.org/10.1001/jamacardio.2021.0475
ISSN: 2380-6583
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)